Get started

Pennystocks

Rapid Recovery Respiratory Failure - COVID-19 TreatmentRelief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary hypertension; and atexakin alfa that has completed Phase I clinical trial to treat peripheral diabetic neuropathy. Relief Therapeutics Holding AG is based in Geneva, Switzerland. RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells - Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites - Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol finance.yahoo.com I think this stock could spike like Moderna Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
OTC:RLFTFLong
by HotCharts
1
First Higher High Since 2011. (LODE)I will be trying to get a fill around 65 cents as that is the high of the previous impulse in this massive downward channel. As of now it looks as it could be a double bottom with strong buys from the 30 cents range. I am attacking at the top of the channel and this can be a risky move. Comstock announced positive income for second quarter which is a bonus. If broke 65 cents than I would look to play at the lows around 30 cents for a long term hold. A breakout of this channel would be a strong sign.
AMEX:LODE
by UnknownUnicorn2319099
Bullish Charts - Plasma Play, FDA Approved Plasma FacilitiesADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey. BREAKING NEWS TODAY - 07/30/2020 ADMA Biologics shares are trading higher following a report suggesting the company is near receiving emergency use authorization of Convalescent Plasma in COVID-19 patients. www.benzinga.com On July 6, 20, ADMA opened a new plasma facility and is awaiting emergency authorization for a second location. finance.yahoo.com With the FDA asking for everyone to donate plasma, this stock could rip! Plasma stocks ripped today and continue to rip. This company already is up and running one plasma facility. Game On! Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ADMALong
by HotCharts
SINTX Technologies: First 1D Golden Cross ever.SINT not only formed its first ever Golden Cross (which is a very bullish technical formation), but also closed the first 1D candle above the 1D MA200 (orange trend-line) since November 2017. This is a very bullish long-term mix for the stock and if the 3.25 Resistance breaks we are ready to buy and triple our investment at 10.00. ** If you like our free content follow our profile to get more daily ideas. ** Comments and likes are greatly appreciated.
NASDAQ:SINTLong
by InvestingScope
2
Avinger On High Alerts. (AVGR)We analyzed this one back in june to identify a massive falling wedge on this penny stock. We have kept it on our radar as it did breakout of the pattern and then retested the lows, treating the old Resistance a ps new support to create what looks to be a double bottom range support. This can be signs of accumulation to push price up. Horizontal levels are the breakout levels you will want to play and accumulate. Remember to diversify, especially on pennystocks
NASDAQ:AVGR
by UnknownUnicorn2319099
Why I am Long on $MMEDFRight now one of the stocks that have my attention, (partly because of Kevin O'Leary) and the rest of its history is Mind Medicine (MindMed Inc.) They are one of the first companies finding a way to neutralize LSD while working on a DMT based therapy drug. Also, the market cap and entry is low. This is one of those stocks where you need to dig deep into the pitch deck and look at competition, market opportunities, and entry price. Right now as a biotech company, it is one of my favorite low priced biotech stocks, and as a long hold in somebody's portfolio, I don't think the risk aversion is too high. That being said, everything I say is on an opinion based basis. Please proceed with caution and invest at your own risk. Do your own due diligence.
MLong
by gamer456148
1
Bullish Charts - Coil, Pennant, Flag - Vans with DronesWorkhorse Group Inc. designs, manufactures, builds, sells, and leases battery-electric vehicles and aircraft in the United States. It operates through two divisions, Automotive and Aviation. The company also develops cloud-based and real-time telematics performance monitoring systems that enable fleet operators to optimize energy and route efficiency. Its products include electric cargo vans, and medium and light-duty pickup trucks, as well as HorseFly delivery drones systems. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015. Workhorse Group Inc. was founded in 2007 and is headquartered in Loveland, Ohio. Today, there was an article on Dow Jones talking about Workhorse Pairing Vans with Drones to Drive Deliveries. www.barrons.com On 07/24/20, there was another article, "Trucks of the Future." & "Electric Trucks are the Future." workhorse.com - Beautiful Electric Truck On 07/23/20, Workhorse reported a purchase order for 20, C-1000 Electric Delivery Trucks. On 07/21/20, Workhorse talks about supplying electric trucks to the Postal Service. Does the news get any better? Yes, on 07/14/20, Workhorse announces Ryder will now offer the C-1000 All-Electric Step Vans for rental locations. On the Daily Chart, it looks to me like it's flagging, Bullish To some, it might look like an uptrending coil or a Bullish Pennant. No matter how you look at the daily chart, it looks to me like a very Bullish setup. RSI is turning up, Bullish OBV is turning up, Bullish Stochastic is turning up, Bullish Accumulation is Bullish I see big things coming for this company! Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:WKHSLong
by HotCharts
Longterm Play For Sharp Corporation? (SHCAY)I've been watching this one for a while and am highly interested based off the technicals. We have been pretty stable in price action around the previous all time low, which also resulted in a large move to the upside. To me this looks like an accumulation play on a double bottom major support. I am accumulating for a very long term trade, with also buys eyed at the 2.30 lows for more accumulation. Pennystocks I like to do 1-3% of working capital in OTC markets.
OTC:SHCAY
by UnknownUnicorn2319099
1
SESEN BIO: Buy opportunity/ emerging Golden Cross.Sesen Bio Inc has turned overbought on the 1D chart (RSI = 86.656, MACD = 0.058, ADX = 57.197) after a strong 10 day bullish sequence that broke above both the 1D MA50 and MA200 periods, but remains a buy opportunity as the MACD remains below the 9-month High. On top of that we have an emerging Golden Cross, while the price seems to be still within the Accumulation Phase. Our short-term Target is 1.500, while if the Lower Highs trend-line breaks, we will re-buy for a 2.500 Target. ** If you like our free content follow our profile to get more daily ideas. ** Comments and likes are greatly appreciated.
SLong
by InvestingScope
3
AXIM Biotechnologies: But opportunity above the 1W MA50.AXIM has turned bullish on the 1W chart (RSI = 64.496, MACD = 0.100, ADX = 26.272) as after the break-out above the 1W MA50 (blue line), it is now on the 3rd straight week of trading above it. This is the first sustainable sequence above the MA50 in years, supported by a strong RSI. That break-out was made at the same time as the 1D Golden Cross, which is typically a very bullish formation. We have added AXIM to our portfolio with a Target Zone of 3.450 - 3.8650. ** If you like our free content follow our profile to get more daily ideas. ** Comments and likes are greatly appreciated.
OTC:AXIMLong
by InvestingScope
BIEI:OTC P-Modeling Pt 1. Cajun Swings of Valor & RedemptionWelcome Hyperspace Traveler. This is Premier BioMedical Inc. +3,000% gains on BIEI by Q1 of 2021. Because?... Well because its the start of 4th industrial revolution..duh.. (eye rolls). Imagine hitting this sequence.. but don't listen to me, I am but a pond scrub a dub. I know, I know.. The disbelief is strong... I feel ya... But ... What if.. Mean Reversion Support, Linear Support, Adam and Eve Support, Cajun Support. Sequence: __________________________________ TP 1 : (0.005) TP2 : (0.01) -refill at .006- TP3 : (0.066) TP 4 : (0.12) by EOY. Q1 2021. ________________________________________ Bullrun---> $1.00 2022. $11.00 ____________________________________ But pshhh.. no way anyone could predict that far ahead with a chart that looks like that. pfffft. Such a mess.. or is it? Curiosity.. it's contagious... Follow along.. Won't wanna miss this. Failure is a necessary component of success. Stay safe out there. Thanks for Pondering the Unknown with Me, Glitch420
OTC:BIEILong
by Glitch420
So, How Does Whales Actually Works?Accumulation Distribution Pump Dump No, whales don't day trade. Whales timeframe are years. Whales will spend YEARS accumulating the asset. Whales will WAIT patiently for the RIGHT TIME. Whales will spread FUD to ensure weak hands sell. Whales have all the money and capital to accumulate and hold. Whales will pump and distribute the price AS HIGH AS possible to retails and suckers. Whales own MAJORITY of the supply of an asset/stock/crypto. Whales has always been there. Without Whales, there is NO LIQUIDITY. Whales provide LIQUIDITY so that the price doesn't move out of the range they want. Whales has been operating financial market for years. If anyone still don't believe this, I am sorry, nothing can be done anymore. There are hopeless and continue to be the slaves of this system and be the victims. Regards. Don't bother to reach out to me.
BEducation
by UnknownUnicorn735418
Moderna in Trouble - ABUS Wins Lawsuit Tied to COVID-19 DrugArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. AFTER HOURS BREAKING NEWS Moderna stock tumbled late Thursday after the biotech lost a patent battle that may jeopardize the financial future of its coronavirus vaccine. Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle, or LNP, technology. Lipid nanoparticles are the delivery system for messenger RNA drugs, including Moderna's coronavirus vaccine, which is known as mRNA-1273. Despite the company's contention, the ruling could cut into profits on any Moderna drug, including mRNA-1273, says SVB Leerink analyst Mani Foroohar. "Revenue concentration in (the coronavirus vaccine) is a central feature of the investment case for Moderna shares," Foroohar said. "Any meaningful royalty burden could hamper Moderna's pricing flexibility and margin profile vs. other players in the SARS-CoV-2 vaccine market." Foroohar called the decision in Arbutus' favor "a disappointing turn for Moderna." "This decision opens the door to a fascinating (and likely protracted) period of investor controversy and debate around the implications of any potential infringement of claims by Arbutus regarding Moderna's use of Lipid Nanoparticle delivery technology, and any further actions Moderna may take to defend their own (intellectual property) position and freedom to operate," he said. NEWS: www.investors.com Where's ABUS going? To $100.00 ...??? On the monthly chart, it looks like $9.00 might be the next stop..? At this point, I am not sure if there is a top right now for ABUS. The news is huge for ABUS and could entitle ABUS to billions in profits and revenue from the COVID-19 vaccine. Intelligent comments welcome. DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ABUSLong
by HotCharts
4
Bullish Charts - FDA Grants Orphan Drug Designation for LymphomaMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado. LATE BREAKING NEWS AFTER HOURS - POSSIBLY A BIG SPIKE IN THE MORNING miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. DAILY CHART IS BULLISH OBV is Bullish MACD turned up Bullish RSi crossed center line and turned up, Bullish PMO is turning up, Bullish This little stock could spike hard. Best of luck everyone! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
Sureshot? SHMP falling wedge to 150% ? #OTCMarkets #OTCBB #OTCQBSHMP appears to be operating in a lovely falling wedge that will likely be coming to it's end at the end of August . Sounds like a perfect late Summer setup for a 100% or more rise ? Looking at it's previous rises it has a similar appearance . Right now it's at .045 and I'd expect it to continue down this falling wedge pattern to probably .025 give or take . My target if it then goes up would be at least that local .618 fib near .0645 which would be 150% approx . but I'm no math expert ! and you should dyor - do your own research . Also I like eating shrimp ( and this is a shrimp company ! ) I would also expect a TD Seq 9 in red to be hit on the 6hr chart ( though we could definitely hit those on the 4hr or 1 day or other timeframe also . ) And the rsi 6hr should be below 30 before this is looking like a buy imo . Keep in mind there is a Gann Fan here that could also see this go to 10 , 12 , or 15 cents but that would be a lot ! Let's keep an eye on this. I've got Trading View alert set for 4hr rsi crossing down 30 just so I don't miss it . Thank you .
OTC:SHMP
by shimmeringpath
Bullish Charts - Robust Earnings, Undervalued & 7.79% YieldNavient Corporation provides education loan management and business processing solutions for education, healthcare, and government clients at the federal, state, and local levels in the United States. It operates through four segments: Federal Education Loans, Consumer Lending, Business Processing, and Other. The company holds and acquires Federal Family Education Loan Program loans that are insured or guaranteed by state or not-for-profit agencies; and performs servicing and asset recovery services on its own loan portfolio, and federal education loans owned by the United States Department of Education and other institutions. It also holds, originates, and acquires consumer loans; and performs servicing activities on its own education loan portfolio, including private education loans, and private education refinance loans. In addition, the company offers revenue cycle management and business processing services; and healthcare services that include revenue cycle outsourcing, accounts receivable management, extended business office support, and consulting engagement for federal, state, and municipal clients; public authorities; and healthcare organizations. Further, it provides customizable solutions for its clients that include hospitals, hospital systems, medical centers, large physician groups, and other healthcare providers; and corporate liquidity portfolio and debt repurchase services. The company was founded in 1973 and is headquartered in Wilmington, Delaware. 07/21/20, Navient Q2 Earnings Blew Away Wall Street Estimates Daily Chart looks Bullish with indicators turning up, positive. BULLISH The company has a current P/E of only 4.94x Current EPS: $1.54 Yield: 7.79% Reported Earnings: Q2 EPS $0.91 Beats $0.47 Estimate Market Cap: 1.5 Billion Institutional Ownership: 98.17% In my opinion, the stock is DIRT CHEAP at current levels. Compare this company's earnings to Bank of America & Wells Fargo, NAVI is blowing away Bank of America earnings along with many other large banks including Wells Fargo! I think NAVI should be trading around $30.00 all day long with the earnings the company is delivering. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:NAVILong
by HotCharts
2
CHEK Check-Cap upside potential - huge volume!Check-Cap Ltd. is a clinical stage medical diagnostics company engaging in the development of ingestible imaging capsule system for colorectal cancer screening. Net Income $-13,840,000, but an encouraging Quick Ratio of 3.69. Looking at the volume, this asset can double its price is seconds. on 5/28/2020 HC Wainwright Reiterated Chek Rating to Buy and the target is $2.00. Not trading advice. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:CHEKLong
by TopgOptions
Spotify Rumored Buyout of SONO - $4 Billion or more, Over $31Sonos, Inc., together with its subsidiaries, designs, develops, manufactures, and sells multi-room audio products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides wireless speakers, home theater speakers, components, and accessories. It offers its products through approximately 10,000 third-party retail stores, including custom installers of home audio systems; and e-commerce retailers, as well as through its Website sonos.com. The company was formerly known as Rincon Audio, Inc. and changed its name to Sonos, Inc. in May 2004. Sonos, Inc. was founded in 2002 and is headquartered in Santa Barbara, California. "We are hearing from a European desk (Spotify is based in Sweden) that Spotify is preparing a roughly $4 billion bid to acquire home entertainment company Sonos (over $31 per share). There has been talk of an interest by Apple in Sonos, but the Sonos board is prepared to go ahead with Spotify. Dont know stock/cash terms." Lets see what happens. Rumor SONO will be bought has been circulating for several months. Today's price action tells us something is brewing! Best of luck folks! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:SONOLong
by HotCharts
1